New cannabis-based analgesic launch faces opposition from hemp industry lobby

A new cannabis-derived pain medication is scheduled for market release on September 1st amid public accusations from the hemp lobby against the developer. The entrepreneur has initiated a public defense, though the specific nature of the allegations remains unverified. The dispute highlights potential regulatory or market-access friction within the emerging cannabis pharmaceutical sector.